Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate February 25, 2025
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage February 25, 2025
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens February 25, 2025
Arcus Biosciences Retains Rights to Casdatifan and Announces Pricing of $150 Million Common Stock Offering February 25, 2025
Myris Therapeutics Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer February 25, 2025
Tempus and Stemline Therapeutics Announce Collaboration to Implement Tempus Next to Support Patients with Metastatic Breast Cancer February 25, 2025
IDEAYA and Gilead Sciences to Evaluate Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC February 19, 2025
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic February 19, 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies February 19, 2025
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer February 11, 2025
Immuneering’s Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) Announced February 11, 2025
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing February 11, 2025
Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics February 11, 2025
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics February 11, 2025
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. February 11, 2025
Nuvation Bio Announces EAP in the US for Taletrectinib in Advanced ROS1-positive NSCLC February 5, 2025
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Ph 2b Trial of IGV-001 in Newly Diagnosed GBM February 5, 2025
Telix Completes Acquisition of Next-Gen Therapeutic Assets and Innovative Biologics Technology Platform February 4, 2025
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Ph 3 Trial of ANKTIVA and PD-1 Checkpoint Inhibitor Combination in NSCLC February 4, 2025
